Stock Taper
SRZNW
SURROZEN, INC.
NASDAQ
$0.00
▼ DOWN 60.53% (-0.00)

KEY STATISTICS

Market Cap$11.22 K
52w High$0.01
52w Low$0.00
Dividend Yield
Frequency
P/E-0.00
Volume26.47K
Shares Out.7.48M

COMPANY

LEADERSHIP

Craig C. Parker
CHIEF EXECUTIVE
Craig C. Parker

COMPENSATION 2026

Salary$605,000
Stock Awards$0
Incentive Plan Pay$287,375
All Other Comp.$0
Total$1,520,085

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 10, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
44

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$467.25K
NOV
11
WED

PRICE

$0.00 ▲ UP 48.35% (+$73.38)

No price history available for SRZNW over this range.

About Surrozen, Inc.

https://www.surrozen.com ↗

Surrozen, Inc. is a biotech firm developing tissue-specific antibodies to modulate the Wnt pathway for regenerative therapies across various organs and diseases.

INDUSTRY

Biotechnology

A PRODUCT SURROZEN, INC. IS KNOWN FOR

SZN-8141
SZN-8141

SZN-8141 is a clinical-stage bifunctional antibody targeting retinal diseases like wet AMD and DME by activating the Wnt pathway and inhibiting VEGF, focusing on ophthalmology.

COMPETITORS

Revenue by Products

IconPRODUCTQ3-2025Q1-2026Q2-2026
Collaboration and license revenue$0 $5M $5M

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
GERMANY$5M $5M
UNITED STATES$1M $500K

INSIDER TRADES

10 PERCENT OWNER
TCG Crossover GP II, LLC
Sale · 162.5K shares
2026-07-22
OFFICER: CHIEF FINANCIAL OFFICER
Maleki Andrew Pedrum
Purchase · 607 shares
2026-06-15
OFFICER: EXEC. VICE PRESIDENT, RESEARCH
Li Yang
Purchase · 1.7K shares
2026-06-15
OFFICER: CHIEF OPERATING OFFICER
Williams Charles O
Purchase · 1.7K shares
2026-06-15

SECTORS PEERS

PEERPRICE
KTTA$0.56COMPARE
REVB$1.05COMPARE
CERO$0.01COMPARE
NKGN$0.00COMPARE
VINC$0.01COMPARE
SYRS$0.00COMPARE
MSPR$0.00COMPARE
VRPX$0.00COMPARE